semaglutide cvot trial Cardiovascular Outcomes (CVOT) Evaluating the Cardiovascular Benefits of

Sources: Lillys oral GLP-1, Orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal phase 3 trials in adults with obesity | Eli Lilly and Company

But beneath that number on the scale, a more complex and sometimes concerning biological story is unfolding

Semaglutide has the ability to improve insulin secretion, which your body uses to regulate blood sugar

5 At the histological level, the hallmark of IBD is recruitment of inflammatory cells, infiltration and activation within the intestinal mucosa and lamina propria, and enhanced production of pro-inflammatory mediators

N.BuchholtzK.CusiK.LinderM.OkanoueT.RatziuV.et al

it is available in four extended-release tablet formulations: 5 mg empagliflozin/2.5 mg linagliptin/1000 mg metformin 10 mg empagliflozin/5 mg linagliptin/1000 mg metformin 12.5 mg empagliflozin/2.5 mg linagliptin/1000 mg metformin 25 mg empagliflozin/5 mg linagliptin/1000 mg metformin